| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7977488 | PHATHOM | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186411 | PHATHOM | Pharmaceutical composition |
Aug, 2030
(6 years from now) | |
Voquezna Triple Pak is owned by Phathom.
Voquezna Triple Pak contains Amoxicillin; Clarithromycin; Vonoprazan Fumarate.
Voquezna Triple Pak has a total of 2 drug patents out of which 0 drug patents have expired.
Voquezna Triple Pak was authorised for market use on 03 May, 2022.
Voquezna Triple Pak is available in capsule, tablet, tablet;oral dosage forms.
Drug patent challenges can be filed against Voquezna Triple Pak from 04 May, 2031.
The generics of Voquezna Triple Pak are possible to be released after 03 May, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
| Generating Antibiotic Incentives Now(GAIN) | May 03, 2032 |
Drugs and Companies using AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE ingredient
NCE-1 date: 04 May, 2031
Market Authorisation Date: 03 May, 2022
Treatment: NA
Dosage: CAPSULE, TABLET, TABLET;ORAL
VOQUEZNA TRIPLE PAK family patents
